M
Mehmet Kanbay
Researcher at Koç University
Publications - 438
Citations - 12822
Mehmet Kanbay is an academic researcher from Koç University. The author has contributed to research in topics: Kidney disease & Medicine. The author has an hindex of 54, co-authored 370 publications receiving 9894 citations. Previous affiliations of Mehmet Kanbay include Bellvitge University Hospital & Fatih University.
Papers
More filters
Journal ArticleDOI
The Role of Uric Acid in the Acute Myocardial Infarction: A Narrative Review.
Atalay Demiray,Baris Afsar,Adrian Covic,Masanari Kuwabara,Charles J. Ferro,Miguel A. Lanaspa,Richard J. Johnson,Mehmet Kanbay +7 more
TL;DR: In this paper, the authors summarized the recent literature data regarding SUA and AMI after providing some background information for the association between UA and coronary artery disease and concluded that decreasing SUA levels is beneficial for outcomes related to acute myocardial infarction (AMI).
Journal ArticleDOI
Pathological features of COVID-19 infection from biopsy and autopsy series.
TL;DR: In this article, the pathological features of COVID-19 derived from biopsy and autopsy series are summarized and compared to other coronavirus-related diseases, including SARS-CoV-2.
Journal ArticleDOI
The dirty little secret of urate-lowering therapy: useless to stop chronic kidney disease progression and may increase mortality.
Guillermo Gonzalez-Martin,Jaime Cano,Sol Carriazo,Mehmet Kanbay,Maria Vanessa Perez-Gomez,Raul Fernandez-Prado,Alberto Ortiz +6 more
TL;DR: In this paper, the authors showed that there is no benefit from urate lowering with allopurinol on the primary endpoint of CKD progression, confirming prior negative results and concluding that the study population could be optimized by enrolling younger non-proteinuric CKD patients with better preserved glomerular filtration rate (GFR).
Journal Article
Hepatic lymphoma metastasis presenting with severe acute liver failure: a rare case.
TL;DR: Karaciger lenfomasi nadir gorulen bir hastalik olup nedeni aciklanamayan karaciger Hastaliklarinin ayirici tanisinda dusunulmesi gereken bir tablodur.
Journal ArticleDOI
Erythropoietin mediates brain-vascular-kidney crosstalk and may be a treatment target for pulmonary and resistant essential hypertension.
TL;DR: This review focuses systematically on erythropoietin, a synthesizable molecule, as a mediator of brain-kidney crosstalk that will be applied to cardiovascular diseases in a clinician-directed fashion.